Nano-X Imaging Releases Q1 2026 Financial Results

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

NNOX|EPS -$0.20 vs -$0.14 est (-21.4%)|Rev $4.3M vs $4.5M est (-18.1%)|Net Loss $33.4M

Nano-X Imaging Ltd. reported a wider-than-expected loss for the first quarter of 2026, missing analyst forecasts on both the top and bottom lines as the medical imaging technology company continues to scale its operations. The company posted a non-GAAP loss per share of $0.20, 21.4% wider than the consensus estimate of a $0.14 loss from 1 analyst. Revenue of $3.7M missed Wall Street’s $4.5M forecast by 18.1%, though the top line showed growth momentum with a 24.0% increase from the year-ago quarter.

The company reported a net loss of $11.2M for the quarter. Teleradiology services led the business, generating $4.3M in revenue and marking a 10.7% year-over-year increase. The segment accounted for the bulk of the company’s quarterly revenue as Nano-X continues building out its novel X-ray imaging technology platform.

Nano-X operated 36 Nanox.ARC systems in various stages of deployment at quarter end, reflecting the company’s ongoing commercialization efforts. Management issued full-year guidance calling for revenue of $35.0M, providing a benchmark for its expansion trajectory through the remainder of 2026.

Wall Street maintains a constructive view on the stock, with analyst consensus standing at 5 buy ratings, 1 hold, and 0 sell recommendations.

A detailed analysis of Nano-X Imaging Ltd.’s quarter follows shortly on AlphaStreet.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.